Immunocore Holdings plc

IMCRSEC EDGAR

Biological Products, (No Diagnostic Substances)(X0)CIK: 1671927

Concept	FY2025	FY2024	FY2023
Revenue from Contract with Customer, Excluding Assessed Tax	$249.4M	$174.4M	$4.1M
Cost of Revenue	$1.0M	$1.1M	$0.00
Research and Development Expense	$163.5M	$101.9M	$100.2M
Selling, General and Administrative Expense	$144.5M	$123.1M	$110.8M
Operating Income (Loss)	-$59.6M	-$51.7M	-$174.6M
Interest Expense	—	—	$5.6M
Other Nonoperating Income (Expense)	-$897.0K	-$1.7M	-$73.0K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$60.9M	-$40.9M	-$179.9M
Income Tax Expense (Benefit)	-$5.6M	$11.7M	$150.0K
Net Income (Loss) Attributable to Parent	-$55.3M	-$52.5M	-$180.0M

Concept	FY2025	FY2024	FY2023
Assets	$1.0B	$597.0M	$526.8M
Assets, Current	$929.9M	$528.8M	$474.0M
Cash and Cash Equivalents, at Carrying Value	$455.7M	$442.6M	$402.5M
Accounts Receivable, after Allowance for Credit Loss, Current	—	$52.1M	$33.6M
Inventory, Net	$5.4M	$4.5M	$692.0K
Liabilities	$648.8M	$228.2M	$187.9M
Liabilities, Current	$212.2M	$139.0M	$100.8M
Accounts Payable, Current	$25.1M	$17.8M	$14.4M
Stockholders' Equity Attributable to Parent	$338.9M	$233.7M	$76.9M
Common Stock, Shares, Outstanding	$50.1M	$49.7M	$48.1M

Concept	FY2025	FY2024	FY2023
Net Cash Provided by (Used in) Operating Activities	$2.9M	-$49.2M	-$143.1M
Net Cash Provided by (Used in) Investing Activities	-$5.4M	-$2.2M	-$1.3M
Net Cash Provided by (Used in) Financing Activities	$34.3M	$145.4M	$288.2M
Payments to Acquire Property, Plant, and Equipment	$5.4M	$2.2M	$1.4M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)